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DObjectives: We sought to evaluate the contemporary results after repair of a complete atrioventricular septal
defect and to determine the factors associated with suboptimal outcomes.
Methods: The demographic, procedural, and outcome data were obtained within 1 and 6 months after repair of
a complete atrioventricular septal defect in 120 children in a multicenter observational study from June 2004 to
2006.
Results: The median age at surgery was 3.7 months (range, 9 days to 1.1 years). The type of surgical repair was
a single patch (18%), double patch (72%), and a single atrial septal defect patch with primary ventricular septal
defect closure (10%). The incidence of residual septal defects and the degree of left atrioventricular valve
regurgitation (LAVVR) did not differ by repair type. The median interval of intensive care stay were 4 days,
ventilation use 2 days, and total hospitalization 8 days. All were independent of the presence of trisomy 21
(80% of the cohort). The in-hospital mortality rate was 2.5% (3/120). The overall 6-month mortality rate
was 4% (5/120). The presence of associated anomalies and younger age at surgery were independently associ-
ated with a longer hospital stay. The age at repair was not associated with residual ventricular septal defect or
moderate or greater LAVVR at 6 months. Moderate or greater LAVVR occurred in 22% at 6 months, and the
strongest predictor for this was moderate or greater LAVVR at 1 month (odds ratio, 6.9; 95% confidence inter-
val, 2.2–21.7; P<.001).
Conclusions: The outcomes after repair of complete atrioventricular septal defect did not differ by repair type or
the presence of trisomy 21. An earlier age at surgery was associated with increased resource use but had no as-
sociation with the incidence of residual ventricular septal defect or significant LAVVR. (J Thorac Cardiovasc
Surg 2011;141:1371-9)The surgical techniques for repairing complete atrioventric-
ular septal defects (AVSDs) have varied among surgeons
and institutions. As perioperative care has improved, the
age at repair has decreased.1 Coincident with the trend to-
ward earlier AVSD repair has been an international demand
for transparency regarding the outcomes data from each in-
stitution performing congenital heart surgery. AVSDs are
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The Journal of Thoracic and Carbeen used to assess both the pediatric heart surgeon’s skill
and the institution’s expertise.2 Controversy remains
regarding the optimal reparative technique and whether
trisomy 21 favorably or unfavorably affects the outcomes.
In the present report, we evaluated the outcomes after repair
of complete AVSD, with particular attention to the type of
surgical repair, patient age at surgery, and the presence of
trisomy 21, and sought to identify the factors associated
with suboptimal outcomes.METHODS
From June 2004 and February 2006, the echocardiographic and clinical
data were collected for children undergoing primary repair of a complete
AVSD across the 7 North American centers constituting the National Heart,
Lung, and Blood Institute-funded Pediatric Heart Network (see Appendix).
The patients with single-ventricle physiology, associated tetralogy of Fal-
lot, or an anomalous pulmonary venous connection were excluded. Pro-
spective data were collected for 103 consecutive, eligible, and
consenting patients who were included in a planned drug trial evaluating
the use of angiotensin-converting enzyme inhibitors in children with left
atrioventricular valve regurgitation (LAVVR) after AVSD repair. To en-
hance the completeness of the multicenter cohort of available subjects,
we retrospectively added other patients who had been screened during
the same period but had not been enrolled in the drug trial (n ¼ 17), under
a waiver of consent.diovascular Surgery c Volume 141, Number 6 1371
Abbreviations and Acronyms
ASD ¼ atrial septal defect
AVSD ¼ atrioventricular septal defect
ICU ¼ intensive care unit
LAVV ¼ left atrioventricular valve
LAVVR¼ left atrioventricular valve regurgitation
VSD ¼ ventricular septal defect
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had been enrolled prospectively. All participating centers had received
institutional review board approval (Clinical trials.gov Identifier:
NCT00113698), and a National Heart, Lung, and Blood Institute-
appointed data and safety monitoring board oversaw the present study.
Clinical and Surgical Data Collection
Using nomenclature from the Society of Thoracic Surgeons, only pa-
tients with a complete AVSD characterized by both a defect in the atrial
septum just above a common AV valve and a nonrestrictive defect in the
ventricular septum just below the AV valve were included.3 Data were col-
lected at surgery and 1 and 6 months postoperatively. The operative reports
from all patients were independently reviewed by 3 investigators who were
unaware of the outcomes for uniformity in defect classification and details
of the repair. Surgical data regarding the use of a single patch, double patch,
or single atrial septal defect (ASD) patch with primary repair of the inlet
ventricular septal defect (VSD) (Australian technique) were recorded.
Standard techniques were used for each type of repair, and the details
have been previously detailed.4-7 The single patch technique used
pericardium for the single patch over both atrial and ventricular
components.4 The double patch techniques used pericardium for the atrial
component and a pericardium, a Dacron, or an expanded polytetrafluoroe-
thelyene patch for the ventricular component.5 The ‘‘Australian,’’ modified
single patch technique used primary suture closure of the ventricular com-
ponent and pericardium for the atrial component.6,7 Annuloplasty included
any additional left atrioventricular valve (LAVV) surgery beyond cleft
closure that resulted in annular diameter reduction.8 The bypass, cross-
clamp, and circulatory arrest times were obtained from the medical record.
Gender, the presence of trisomy 21, associated defects, age and weight
at surgery, complications requiring intervention, and the duration of me-
chanical ventilation, intensive care, and total hospitalization were obtained
from the medical records. The weight-for-age z-scores were calculated us-
ing gender-specific reference values for trisomy 219 and normal children,10
as appropriate. Growth failure was defined as a weight-for-age z-score of
less than2. The heart failure scores were determined using the Ross Heart
Failure classification11 and were obtained 6 months after surgery. Cardiac
medications were recorded at the 1- and 6-month echocardiograms.
Echocardiographic Data
For the 103 patients enrolled prospectively, the echocardiograms were
performed within 1 month after repair and at the 6-month follow-up visit
using a standard protocol. The echocardiograms were sent to a core
laboratory, where measurements were made by a single observer. For the
17 patients enrolled retrospectively, only 1-month echocardiograms were
available, with all measurements made by each center’s echocardiog-
raphers. The left ventricular (LV) ejection fraction was calculated using
Simpson’s rule or the (5/6)*area*length method.12 LV dysfunction was de-
fined as a LVejection fraction of less than 55%. The degree of LAVVRwas
subjectively graded as none/trace, mild, moderate, or severe according to
the width of the color Doppler jets in relation to the surrounding cham-
bers.13 LAVVR was considered significant if graded moderate or severe.1372 The Journal of Thoracic and Cardiovascular SurColor Doppler was also used to demonstrate any residual ASD or VSD,
and diameters greater than 3 mm were considered significant.2 Pulsed
Doppler interrogation of the LAVV inflow and LVoutflow was performed,
and a LAVV mean gradient of 7.5 mm Hg or greater and LVoutflow peak
instantaneous gradient of 20 mmHg or greater were considered significant.
After study conclusion, the degree of preoperative AVVR was retrospec-
tively collected and graded similarly by each center’s echocardiographers.
Statistical Analysis
The data are summarized using frequencies, medians, and means with
the standard deviation, as appropriate. We compared the outcomes accord-
ing to age at surgery, the presence or absence of trisomy 21, and the type of
surgical technique. Subgroup differences in the categorical variables were
assessed using the chi-square test and Fisher’s exact test. Subgroup differ-
ences in continuous variables were assessed using the t test, analysis of
variance, or nonparametric testing for highly skewed outcomes. The paired
t test and McNemar’s test were used to assess the change in outcomes dur-
ing the 6-month follow-up period. Nonparametric generalized additive
modeling was used to identify nonlinear associations between covariates
and outcomes. For age at surgery, we used piecewise linear regression anal-
ysis to determine the optimal cutpoint associated with particular outcomes.
We applied a log transformation to the outcomes of length of stay, ventila-
tor duration, and intensive care unit (ICU) stay to assess the association
with potential predictors using linear regression analysis. Univariate asso-
ciations between the outcome of at least moderate LAVVR and patient/sur-
gical factors were identified using logistic regression analysis. All variables
significant at the 0.20 level on univariate analysis were evaluated for inclu-
sion in the multivariate regression models for the length of stay, ventilator
duration, ICU stay, and at least moderate LAVVR. We used a test of inter-
action to assess whether the association of age at surgery ( 2.5 vs>2.5
months) on the hospital outcomes varied with the number of concurrent
procedures. Within the subgroups defined by the number of surgeries, un-
adjusted P values are reported for the association between age at surgery
and outcome. All analyses were performed using Statistical Analysis
Systems statistical software, version 9 (SAS Institute, Cary, NC).
RESULTS
Subjects and Clinical Outcomes at Surgery
The study group included 120 patients (80% with tri-
somy 21) who underwent repair at a median age of 3.7
months (Table 1). The median weight-for-age z-score at re-
pair was1.4. Of the 120 patients, 37 (31%) had growth
failure (weight-for-age z-score<2) and 10 (8%) weighed
less than 3 kg. Excluding a patent foramen ovale or small
additional secundum ASD, additional cardiac defects re-
quiring some concurrent surgical procedure were present
in 58 patients (48%). The most common concurrent proce-
dure was ligation of an arterial duct in 53 patients (44%).
Other concurrent surgical procedures included repair of
an aortic arch abnormality in 6, closure of a remote VSD
in 2, venous baffle for anomalous systemic venous drainage
in 2, plasty of a stenotic right upper pulmonary vein in 1,
and subaortic stenosis resection in 1. A total of 7 patients
(6%) were returned to bypass during the initial operative
procedure to address residual anatomic lesions; 3 to address
significant LAVVR, 3 to address both LAVVRand a residual
VSD, and 1 to address significant right-sided atrioventricu-
lar valve regurgitation.
Overall, 5 patients died (4%). Of these 5 patients, 3 died
before hospital discharge (age at repair was 15 days forgery c June 2011
TABLE 1. Results of 120 complete AVSD repairs by surgical technique
Variable Overall Single Double Australian P Value
Patients (n) 120 21 87 12
Age at AVSD repair (mo) .02*
Mean  SD
Median
3.8  1.8
3.7
4.4  1.1
4.4
3.8  2.0
3.6
2.6  1.3
2.8
Male (%) 41 38 44 25 .5
Trisomy 21 (%) 80 91 83 42 .004*
Zone of apposition ‘‘cleft’’ closure (%) 93 91 94 92 .6
Annuloplasty (%) 24 14 30 0 .03*
Bypass time (min) 112  36 131  26 110  38 90  25 .005*
Crossclamp time (min) 82  31 95  23 81  33 62  19 .01*
Circulatory arrest (yes) 8 19 6 8 .1
Concurrent surgery, excluding PFO/small
ASD (%)
.7
0 52 67 49 42
1 42 29 44 50
2 6 5 6 8
3 1 0 1 0
Total ICU stay (d) .8
Mean  SD
Median
8.6  16.8
4
6.2  9.7
4
9.0  18.5
4
9.1  14.4
4
Total ventilator use (d) .8
Mean  SD
Median
6.0  14.9
2
4.1  8.3
2
6.3  16.1
2
7.2  16.2
2
Total hospital stay (d) .1
Mean  SD
Median
13.2  20.4
7
10.4  13.6
7
15.3  22.3
9
15.3  16.1
9
Death by 6 mo (n) 5 (4.2) 0 (0) 4 (4.6) 1 (8.3) .6
Reoperation by 6 mo (n) 5 (4.2) 2 (9.5) 2 (2.3) 1 (8.3) .2
AVSD,Atrioventricular septal defect; PFO, patent foramen ovale; ASD, atrial septal defect; ICU, intensive care unit. Data in parentheses are percentages. *Statistically significant.
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aortic arch obstruction, and 1.9 months for a patient with tri-
somy 21 and significant growth failure). The in-hospital
deaths occurred 3 months, 2.3 months, and 5 days after re-
pair. The 2 patients who died after hospital discharge had
undergone repair at age 3.7 months and 5 months, and the
deaths were attributed to pulmonary hypertension (2 and
5 months after discharge). Early reoperation (within
6 months of the initial surgery) was needed only for
significant LAVVR and was performed in 5 patients
(4 were<2.5 months old at the initial surgery; 1 of these
patients died in-hospital, as reported at the beginning of
this paragraph).
The median interval of mechanical ventilation, ICU stay,
and hospitalization was 2 days (range, 1–100 days), 4 days
(range, 1–127 days), and 8 days (range, 4–128 days), re-
spectively. In-hospital complication data were recorded
for the 103 prospectively enrolled patients, of whom 42
(41%) had at least 1 complication (Table 2).
Clinical Outcomes Assessed at 1 and 6 Months
The 17 screened patients whowere added retrospectively,
the 5 patients who died, and 13 patients who were alive
but did not return for follow-up had no detailed clinical orThe Journal of Thoracic and Carechocardiographic re-evaluation data available at 6 months.
In addition, 2 patients had technically unacceptable echo-
cardiograms as determined by the core laboratory. There-
fore, of the original cohort of 120 patients, 85 clinical
data pairs and 83 echocardiographic data pairs were avail-
able to explore the potential changes over time between
1 and 6 months after surgery.
At 1 month postoperatively, the cardiac medications in-
cluded angiotensin-converting enzyme inhibitors in 27
(23%), digoxin in 13 (11%), diuretics in 114 (96%), and
b-blockers in 5 (4%) of 119 patients. By 6 months of
follow-up, the use of angiotensin-converting enzyme
inhibitors had decreased to 16% (14/85), diuretics to
20% (17/85), and digoxin to 2% (2/85); no patient was tak-
ing a b-blocker. Overall, growth had improved by 6 months
of follow-up (weight-for-age z-score1.5  1.2 within 1
month of surgery vs0.7  1.0 at 6 months, P< .0001),
and the prevalence of growth failure had decreased from
31% to 11% (P < .001). The change in the weight-
for-age z-score was similar between those with and without
trisomy 21 (þ0.7 1.1 vsþ1.2 0.8, P¼ .08; Table 3). Us-
ing the Ross heart failure scoring system, 79 patients were
in class I, 3 were in class II, and 3 were in class III at 6
months after surgery.diovascular Surgery c Volume 141, Number 6 1373
TABLE 2. Complications requiring treatment in 103 patients
Complications* Frequency %
Infection 11 11
Bacterial positive sepsis 6
Wound infection 3
RSV bronchiolitis 1
Clostridium difficile diarrhea 1
Pleural effusion 14 14
Pericardial effusion 6 6
GI complication, including NEC 15 15
Arrhythmia 9 9
Atrial flutter 3
Junctional ectopic tachycardia 1
Ventricular tachycardia 5
Complete heart block 0
Cardiopulmonary resuscitation 4 4
Delayed sternal closure 2 2
Intubated>2 wk postoperatively 5 5
Renal failure (elevated creatinine>7 d) 2 2
Vocal cord injury 2 2
RSV, Respiratory syncytial virus; GI, gastrointestinal; NEC, necrotizing enterocolitis.
*Complications were not mutually exclusive.
TABLE 3. Results stratified by trisomy 21 status
Variable
Trisomy 21
P
Value
Yes
(n ¼ 96)
No
(n ¼ 24)
Age at AVSD repair (mo) 3.8  1.5 3.7  2.8 .9
Male (%) 41 42 1.0
Surgical management
Patch technique (%) .004*
Single 20 8
Double 75 63
Australian 5 29
Zone of apposition ‘‘cleft’’
closure (%)
95 88 .4
Annuloplasty (%) 24 25 1.0
Bypass time (min) 115  37 100  30 .07
Return to bypass (%) 4 13 .2
Crossclamp time (min) 83  32 77  28 .4
Circulatory arrest (yes) 6 (6) 4 (17) .1
Concurrent surgery, excluding
PFO/ASD (%)
50 46 .4
In hospital complication (%) 38 54 .2
In-hospital complications (n) 0.7  1.1 1.4  1.8 .05*
Total ICU stay (d) (median) 8  17 (4) 11  17 (4) .6
Total ventilator use (d)
(median)
6  15 (2) 8  16 (2) .8
Total hospital stay (d) (median) 13  18 (8) 19  28 (9) .4
Reoperation by 6 mo (n) 2 (2) 3 (13) .06
Death by 6 mo (n) 4 (4) 1 (4) 1.0
Growth
Weight-for-age z-score at
surgery
1.3  1.0 2.4  1.1 < .001*
Weight-for-age z-score<2 at
surgery (%)
21 71 < .001*
Weight-for-age z-score at 6 mo 0.6  1.0 1.3  0.8 .008*
Weight-for-age z score<2
at 6 mo (%)
7 27 .05*
Change in weight-for-age
z-score at 6 mo
þ0.7  1.1 þ1.2  0.8 .08
Echocardiographic findings (%)
Residual ASD at 1 mo 14 30 .09
Residual ASD at 6 mo 4 0 1.0
Residual VSD at 1 mo 47 52 .7
Residual VSD at 6 mo 11 20 .4
Moderate/severe LAVVR
Preoperative 17 38 .05*
At 1 mo 21 38 .1
At 6 mo 20 33 .3
VSD,Ventricular septal defect; LAVVR, left atrioventricular valve regurgitation; other
abbreviations as in Table 1. *Statistically significant.
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Residual shunts were common, but most were small. At
the echocardiogram performed within 1 month after sur-
gery, 17 (16%) of 105 patients had a residual ASD but
only 1 was greater than 3 mm. Of 117 patients, 56 (48%)
had a residual ventricular shunt, 9 of which were greater
than 3 mm. By 6 months, no patient had an ASD greater
than 3 mm and 1 had a VSD of 3 3 4 mm. The prevalence
of left ventricular dysfunction was relatively common early
after surgery but had improved significantly by 6 months af-
ter surgery (35% vs 10%, P<.001). No patient had LAVV
stenosis or left ventricular outflow obstruction at either
follow-up point. The prevalence of moderate or greater
LAVVR did not change significantly with time: 24%within
1 month and 22% at 6 months. On multivariate analysis, the
strongest predictor of important LAVVR at 1 month was
a greater number of in-hospital complications (odds ratio
1.4, 95% confidence interval 1.0–1.9, P ¼ 0.03). The
only predictor of important LAVVR at 6 months was mod-
erate or greater LAVVR at 1 month (odds ratio, 6.9; 95%
confidence interval, 2.2–21.7; P<.001).
Comparison of Surgical Technique
Double patch closurewas the most widely used technique
for repair in 87 (72%) of 120 patients, followed by single
patch closure in 21 patients (18%) and the Australian tech-
nique in 12 (10%), although the repair type varied by center
(P ¼ .002; Table 1). The repair type was also associated
with age, with the Australian technique performed in youn-
ger patients (2.6 1.3 months old, P¼ .02) compared with
the single (4.4 1.1 months old) or double patch (3.8 2.0
months old) techniques. The single patch technique was
used more frequently in patients with trisomy 21, and the1374 The Journal of Thoracic and Cardiovascular SurAustralian technique was used least in patients with trisomy
21 (P ¼ .004). The bypass times were significantly longer
for the single patch (131 26 minutes, P¼ .005) compared
with the double patch (110  38 minutes) and Australian
(90  25 minutes) techniques. The crossclamp times
were also longer with the single patch technique (95  23
minutes, P ¼ .01) compared with the double patchgery c June 2011
TABLE 4. Results stratified by age at repair
Variable
Age  2.5 mo
(n ¼ 25)
Age>2.5 mo
(n ¼ 95)
P
Value
Male (%) 52 38 .3
Surgical management
Zone of apposition ‘‘cleft’’
closure (%)
86 95 .2
Annuloplasty (%) 28 23 .6
Double orifice mitral valve (%) 0 4 .6
Patch technique (%) .04*
Single 4 21
Double 76 72
Australian 20 7
Bypass time (min) 111  48 112  33 1.0
Return to bypass (%) 8 5 .6
Crossclamp time (min) 82  41 82  28 1.0
Circulatory arrest 5 (20) 5 (5) .03*
Concurrent surgery, excluding
PFO/ASD (n)
0.8  0.8 0.5  0.6 .06
In-hospital complication (%) 56 37 .1
In-hospital complications (n) 1.6  2.0 0.6  0.9 .02*
Total ICU stay (d) (median) 16  24 (6) 7  14 (4) .002*
Total ventilator use (d)
(median)
14  24 (5) 4  11(2) .006*
Total hospital stay (d) (median) 24  26 (12) 12  18 (8) .005*
Reoperation by 6 mo (n) 4 (16) 1 (1) .007*
Death by 6 mo (n) 3 (12) 2 (2) .06
Growth
Weight-for-age z-score at
surgery
1.3  1.2 1.6  1.1 .3
Weight-for-age z-score<2
at surgery (%)
28 32 .8
Weight-for-age z-score at 6 mo 0.9  0.9 0.7  1.0 .4
Weight-for-age z-score<2
at 6 mo (%)
19 9 .4
Change in weight-for-age
z-score at 6 mo
0.5  1.1 0.8  1.0 .3
Echocardiographic findings (%)
Residual ASD at 1 mo 22 15 .5
Residual ASD at 6 mo 0 4 1.0
Residual VSD at 1 mo 52 47 .7
Residual VSD at 6 mo 13 13 1.0
Preoperative moderate/severe
LAVVR
24 20 .8
Moderate/severe LAVVR at
1 mo
25 24 1.0
Moderate/severe LAVVR at
6 mo
13 25 .5
Abbreviations as in Tables 1 and 3. *Statistically significant.
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niques. No patient with a single patch closure required
repeat bypass compared with 5 (6%) of 87 with a double
patch and 2 (17%) of 12 with the Australian technique
(P ¼ .1). The zone of apposition or cleft was closed in
93% and the difference was not significant across repair
types. The prevalence of residual ASD and VSD was notThe Journal of Thoracic and Cardifferent among the surgical techniques. The percentage
of subjects with significant LAVVRwas not different across
the repair types at 1 or 6 months after surgery. The total ICU
days, days of ventilator use, and days in the hospital and
mortality and need for reoperation by 6 months did not
differ by repair type, even after adjusting for age at repair.
Comparisons by Presence of Trisomy 21
Trisomy 21 was present in 96 (80%) of the 120 patients
(Table 3). Age at surgery, gender, race, and ethnicity were
similar in those with and without trisomy 21. As stated pre-
viously, the repair types differed by trisomy 21 status, most
notably with more repairs using the Australian technique in
the non-trisomy 21 group (29% vs 5%). The hospital
courses were similar, with the exception of the number of
in-hospital complications (greater in the non-trisomy 21
group). The mortality rate at 6 months was identical at
4%, but a trend was seen toward more reoperations in the
first 6 months for those without trisomy 21 (13% vs 2%,
P ¼ .06). Moderate or severe LAVVR was more likely in
the non-trisomy 21 group before AVSD surgery. However,
the prevalence of LAVVR did not differ at 1 and 6 months
after surgery. Using the trisomy 21 or normal growth stan-
dards, as appropriate, patients without trisomy 21 had sig-
nificantly lower weight-for-age z-scores (2.4  1.1 vs
1.3  1.0, P ¼ .001) and a greater prevalence of growth
failure (71% vs 21%, P<.01) at repair than those with tri-
somy 21. This difference persisted at both 1 and 6 months of
follow-up, and, although both groups improved in growth,
no significant difference was seen in the degree of improve-
ment by group during the first 6 months after repair.
Comparison by Age at Repair
We found that adverse outcomes were negatively corre-
lated with age at repair from birth to about 2.5 months but
did not vary by age after 2.5 months (Table 4). When we as-
sessed age as a dichotomous variable, we found that adverse
outcomes such as a longer hospital stay, longer ICU stay,
longer ventilator use, and greater complication rate were
seen in those patients who had undergone repair before
2.5 months of age comparison with those who had under-
gone repair after 2.5 months of age (Table 4). A trend was
seen toward greater mortality by 6 months in those younger
than 2.5 months (12% vs 2%, P¼ .06), and the percentage
of subjects requiring reoperation within the first 6 months
was greater for those 2.5 months old or younger at surgery
(16% vs 1%, P ¼ .007). Also, differences were in the sur-
gical repair technique, with a greater percentage of repairs
using the Australian technique for those 2.5 months old or
younger. A greater percentage of younger subjects had
circulatory arrest (20% vs 5%). The growth parameters,
prevalence of residual defects, and prevalence of moderate
to severe LAVVR were similar between the younger and
older cohorts.diovascular Surgery c Volume 141, Number 6 1375
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FIGURE 1. Piecewise regression fit for ventilator duration, intensive care
unit (ICU) stay, and hospital stay by age at surgery. Solid line indicates pre-
dicted values from regression versus age at surgery. Each outcome corre-
lated negatively with age at surgery from birth to about 2.5 months but
did not vary by age after 2.5 months.
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FIGURE 2. Box plots of ventilator duration, intensive care unit (ICU)
stay, and hospital stay by age group and number of concurrent surgeries.
P values from linear regression modeling of log-transformed outcome.
Asterisk denotes group mean. Lower, middle, and upper edges of boxes
represent 25th, 50th, and 75th percentiles, respectively.
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The number of ventilator days, ICU days, and hospital
days exhibited a dramatic right-skew. Thosewho had under-
gone repair at 2.5 months old or younger had a longer dura-
tion of mechanical ventilation and longer ICU and total
hospital stays (Figure 1 and Table 4). We hypothesized
that the relationship between these 3 outcomes and the num-
ber of surgeries performed concurrently with AVSD repair
might be dependent on the age at surgery.We found a signif-
icant interaction for all 3 outcomes (all P<.01). In those 2.5
months old or younger at surgery, the resource use increased
with each additional surgery, particularly for those with 2 or
more concurrent procedures (Figure 2). For patients older
than 2.5 months at surgery, the ventilator days and ICU
and total hospital stay were independent of the number of
concurrent surgeries.
DISCUSSION
The present multicenter study was uniquely suited to
explore the effects of differences in surgical technique and1376 The Journal of Thoracic and Cardiovascular Surthe factors related to specified controversial demographic
variables such as age and the presence of trisomy 21 on out-
come measures. The surgical repair of complete AVSD is
routinely performed during infancy, although no consensus
has been reached regarding the ideal timing to balance the
risk of congestive heart failure symptoms against the greater
technical operative risks. Single-center reports encompass-
ingmore than 1 decade have demonstrated that earlier repair
at<3 or 4 months of age can be associated with lower hos-
pital mortality14,15 and a lower risk of later reoperation
compared with those undergoing repair at an older age.15
In our series, the median age at repair was 3.7 months,
and the outcomes were generally good. The in-hospital mor-
tality rate was low (2.5%), and reoperation within 6 months
for severe LAVVR occurred in 4%, commensurate with the
data from recent single-center reports.16 Significant residual
atrial or ventricular shunts were uncommon and tended to be
small, with resolution within 6 months of repair. Similar to
other reports, moderate or greater LAVVR, as assessed bygery c June 2011
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and was present in 22% at 6 months.17
Classic repairs for complete AVSD have used either
a single patch to close both atrial and ventricular defects, ne-
cessitating division and resuspension of the common atrio-
ventricular valve,4 or a double patch technique in which
the valve is not divided and individual patches are used to
close each defect.5 More recently, a modified single patch
technique has been described that avoids the use of a patch
to close the VSD (Australian technique).6,7 Although
reports comparing the various techniques have been
limited by era, surgeon, and institutional experience,
general equivalence with respect to efficacy has been
suggested for the short- to medium-term outcomes.16,18
Overall, the double patch technique was performed more
often (72%) in our series; however, we found considerable
variation in the repair type across the participating centers.
Previous studies comparing the outcomes of different
surgical techniques for the repair of complete AVSD have
been limited to single-center reports using historical con-
trols. Ourmulticenter, contemporary findings have generally
supported the findings from these previous retrospective re-
ports and showed no differences in residual septal defects,
degree of LAVVR, need for reoperation by 6 months, or
postoperative ICU and hospital stay by repair type. In our co-
hort, the children who underwent the Australian technique
were younger and less likely to have trisomy 21. Although
we did not have the data to confirm this, one might speculate
that the subgroup of patients without trisomy 21 might be
more likely to have a comparatively smaller VSD, making
the Australian type repair more appealing. We corroborated
previously noted differences in surgical management with
the Australian technique requiring shorter bypass and cross-
clamp times.16,18 Although speculative, it is plausible that
a surgeon might have selected the Australian technique as
the preferred repair in the youngest and most symptomatic
patients to allow the surgery to be completed faster and
with less manipulation of the common valve.
We found important differences that were previously un-
reported. First, a lower frequency of additional annuloplasty
modifications of the LAVVwas found among those repaired
with the Australian technique (0% Australian, 14% single
patch, 30% double patch). Second, the need to return to by-
pass for surgical revision of the initial operation occurred
more frequently with the Australian technique than with
the other techniques. This might have reflected the younger
ages at repair or the surgeon and institutional learning curve
with this newer type of repair. Our analysis failed to identify
a superior method for complete AVSD repair. We surmised
that it is surgeon preference, institutional experience, and
familiarity with a specific technique, rather than the tech-
nique itself, that provides the best outcomes.
Historically, patients with AVSD and trisomy 21 com-
pared with those without trisomy 21 have been reported toThe Journal of Thoracic and Carhave better outcomes with fewer reoperations.19,20 More
recent reports have suggested that the presence of trisomy
21 has no effect on postoperative survival.21 In our series,
some preoperative and intraoperative differences were pres-
ent between the 2 groups, but the outcomes were similar.
Fewer patients with trisomy 21 had moderate or severe
atrioventricular valve regurgitation on the preoperative
echocardiogram. Significantly fewer patients with trisomy
21 underwent repair using the Australian technique (5%
vs 29%). We also found a trend toward decreased early re-
operation by 6 months in those with trisomy 21 (2% vs
13%). Although others have suggested the ‘‘protective’’ in-
fluence of trisomy 21 for infants undergoing surgery for
AVSD might in part be because they are more likely to
have the balanced form of AVSD and less likely to have het-
erotaxy syndrome, we did not collect the data required to
test those features.22 The most striking difference con-
cerned the comparative growth issues. Although it is well
known that subjects with trisomy 21 will be smaller than
those without trisomy 21, and, among those with trisomy
21, those with congenital heart disease will be smaller
than those without heart defects,23 growth comparisons be-
tween the children with and without trisomy 21 and the
same heart defect have not been previously reported. We
found those without trisomy 21 were much more likely to
have growth failure at surgery (71% vs 21%). At 6 months
after repair, the patients without trisomy 21 exhibited con-
siderable ‘‘catch up’’ growth but were still more likely to
have growth failure (27% vs 7%). Patients with unrepaired
AVSD and trisomy 21 have greater pulmonary vascular re-
sistance than children with normal chromosomes.24 There-
fore, subjects without trisomy 21 might be expected
preoperatively to have a greater net left to right shunt and
more growth failure compared with those with trisomy 21.
An ongoing trend is present toward earlier repair of
AVSD; thus, we attempted to find a lower bound for patient
referral in this group. Considering the age at repair as a con-
tinuous variable, we found that adverse outcomes were neg-
atively correlated with repair at age younger than 2.5
months but did not vary by age beyond 2.5 months. When
comparing these 2 groups (using 2.5 months as the cutoff),
we found some important differences. The repair type dif-
fered by age at surgery, with fewer repairs using the single
patch technique and more using the Australian technique in
the younger group. The younger group was more likely to
undergo circulatory arrest that appeared directly related to
the need to perform concurrent additional surgeries such
as aortic arch augmentation. The resource use was also
strikingly different. Subjects undergoing repair at younger
than 2.5 months old required a longer duration of mechan-
ical ventilation and longer ICU and total hospital stays.
The present study was sponsored by the Pediatric Heart
Network, an entity devoted to creating evidence-based
medical practice in pediatric cardiology and cardiacdiovascular Surgery c Volume 141, Number 6 1377
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Dsurgery. The 7 participating surgical centers involved in the
present study appreciated the importance of sharing the out-
come data and anticipated that the current data might be
used as a comparative benchmark for efforts at additional
improvements in the treatment of patients with complete
AVSD.
Study Limitations
The multicenter and observational nature of the present
study precluded standardization and central interpretation
of all measurements. Reliable and validated echocardio-
graphic methods for the quantification of LAVVR in pediat-
ric patients were not available; thus, we chose to use
a qualitative assessment according to the color Doppler
evaluation by a single core laboratory echocardiographer.
The follow-up of the present cohort was limited to 6
months, precluding assessment of longer term complica-
tions or the need for reoperation. The nonrandom distribu-
tion of repair type limited the ability to distinguish
between age effect and surgical technique. Similarly, the
age at surgery was not randomly distributed but was skewed
toward an older age; therefore, the smaller number of sub-
jects with repairs undertaken before 2.5 months of age
might have limited the power to detect associations between
age at repair and certain outcomes.
CONCLUSIONS
We evaluated the outcomes after repair of complete
AVSD, with particular attention to surgical repair type,
age at surgery, and the presence of trisomy 21. We found
marked institutional variability in repair type in the current
era. Mortality and morbidity, despite the repair type or pres-
ence of trisomy 21, were low. Age at repair of 2.5 months or
younger and the need for concurrent surgical procedures
were not associated with residual defects or the degree of
LAVVR but were associated with longer postoperative
ventilator, ICU, and total hospital duration.
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